Responses
Immune cell therapies and immune cell engineering
Original research
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.